Podcasts

Difficult-to-treat disease in Rheumatology Podcast Professors Iain McInnes and Peter Nash

Join Professor Iain McInnes from the University of Glasgow, and Professor Peter Nash from the Griffith University in Brisbane, as they discuss the concept of difficult-to-treat disease in rheumatology.

Discussing axSpA: Secukinumab treatment outcomes on sustained remission and skeletal health in axSpA

Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered treatment outcomes in European real-world patients with axSpA and PsA, treated with secukinumab and the effects of secukinumab on skeletal microarchitecture and vertebral fractures in patients with axSpA.

Discussing RA: Impact of TOF on BMI, UPA monotherapy in MTX-IRs, and JAKis vs TNFis treatment

Join Professor Iain McInnes and Professor Rieke Alten for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in RA.

In this episode, they discuss three papers: the impact of TOF treatment on weight and BMI in RA patients, to that of alternate treatment options for RA patients with prior MTX-inadequate response, and the treatment of JAKis versus TNFis in RA.

Podcast: AuToDeCRA, June 2025

Join Professor Ian McInnes from the University of Glasgow, and Professors John Isaacs and Andrew Cope, as they discuss the latest AuToDeCRA study and what this means for rheumatology.

Discussing PsA: Real-world data on biologic switching and the development of EMMs

Join Professors Philip Mease and Laura Coates and as they discuss the top publications in the world of PsA. This month, the conversation covered a discussion on biologic switching for the treatment of PsA using real-world data as well as the development of extramusculoskeletal manifestations in PsA and axSpA patients treated with upadacitinib.

Discussing RA: MACE in RA, data from the "JAK-pot" study, and combination therapy in MTX-IR RA

Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest updates in RA.

In this episode, he discusses two papers: risk of MACE in patients with RA treated with JAKis compared to bDMARDs from the “JAK-pot” study, and the efficacy and safety of zimlovisertib, ritlecitinib and tofacitinib, alone and in combination, in patients with RA and an inadequate response to MTX.